AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24700526 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland grade III anterior‐to‐posterior joint mobilization
Number of subjects: 30
Study 24700526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 21987386 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (4 mg intravenously every 6 months for 5 years)
Number of subjects: 602
Study 21987386 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (4 mg intravenously every 6 months for 5 years)
Number of subjects: 602
Study 20300023 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest press on Swiss ball
Number of subjects: 16
Study 20300023 — intervention group
Group type: COMPARATOR
Intervention: Chest press on bench
Number of subjects: 16
Study 20300023 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder press on Swiss ball
Number of subjects: 16
Study 20300023 — intervention group
Group type: COMPARATOR
Intervention: Shoulder press on bench
Number of subjects: 16
Study 18824714 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 363
Study 18824714 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 363
Study 15907848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day) and Vitamin E (400 IU/day)
Number of subjects: 60
Study 15907848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11874164 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 210
Study 11874164 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline naive CD4+ cell count
Number of subjects: 210
Study 11874164 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 210
Study 11350109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million IU streptokinase
Number of subjects: 447
Study 9420390 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and prednisolone alternated with chlorambucil
Number of subjects: 30
Study 9420390 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 30
Study 8320005 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft laser treatment (As-Ga and He-Ne)
Number of subjects: 28
Study 8320005 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 28
Study 3529799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine (10 mg/day for 3 days)
Number of subjects: 7
Study 3529799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neostigmine (45 mg/day for 3 days)
Number of subjects: 7
Study 3529799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine (1 mg)
Number of subjects: 7
Study 3529799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (1.5 mg)
Number of subjects: 7
Study 29080210 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW)
Number of subjects: 0
Study 26890454 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 40
Study 26890454 — intervention group
Group type: COMPARATOR
Intervention: Traditional rotating drills
Number of subjects: 40
Study 26890454 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 40
Study 26214887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gukang Capsules plus Calcium Carbonate Tablets
Number of subjects: 108
Study 26214887 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate Tablets
Number of subjects: 108
Study 23953056 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/d continuously
Number of subjects: 233
Study 23953056 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib 1250 mg/d continuously plus capecitabine 2000 mg/m2 per day on days 1-14 of each 21-d cycle
Number of subjects: 233
Study 23953056 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 233
Study 23953056 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 233
Study 21148503 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 326
Study 21148503 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (50 mg/kg, 6 divided doses over 3 days)
Number of subjects: 326
Study 18324564 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarette smoking
Number of subjects: 1343
Study 18324564 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy-aided quit attempt
Number of subjects: 1343
Study 17718286 — intervention group
Group type: EXPERIMENTAL
Intervention: Chula-clamp
Number of subjects: 140
Study 17718286 — intervention group
Group type: COMPARATOR
Intervention: Standard manual compression
Number of subjects: 140
Study 12665973 — intervention group
Group type: EXPERIMENTAL
Intervention: EX70 (70 eccentric contractions)
Number of subjects: 26
Study 12665973 — intervention group
Group type: EXPERIMENTAL
Intervention: EX30 (30 eccentric contractions)
Number of subjects: 26
Study 12665973 — intervention group
Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 26
Study 11212413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with oxygen and 67% nitrous oxide
Number of subjects: 70
Study 11212413 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with oxygen and 67% nitrous oxide
Number of subjects: 70
Study 11212413 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane with oxygen and 67% nitrous oxide
Number of subjects: 70
Study 11212413 — intervention group
Group type: COMPARATOR
Intervention: Control group (oxygen, 50% nitrous oxide, and original concentration of each volatile anesthetic)
Number of subjects: 70
Study 8922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily (with some patients receiving 800 mg for part of treatment)
Number of subjects: 27
Study 8922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily
Number of subjects: 27
Study 8922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg daily
Number of subjects: 27
Study 8922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 27
Study 1562701 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for lung cancer, two examinations per year
Number of subjects: 0
Study 1562701 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for lung cancer
Number of subjects: 0
Study 30028033 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic cognitions regarding the self, world, and self-blame
Number of subjects: 290
Study 30028033 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 290
Study 30028033 — intervention group
Group type: COMPARATOR
Intervention: Demographics
Number of subjects: 290
Study 28167470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with Shexiang baoxin pills therapy
Number of subjects: 131
Study 28167470 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel therapy (Control)
Number of subjects: 131
Study 26319228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) infusion set (microneedle design B)
Number of subjects: 43
Study 26319228 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) infusion set (Rapid-D)
Number of subjects: 43
Study 26319228 — intervention group
Group type: COMPARATOR
Intervention: Intradermal (ID) infusion set
Number of subjects: 43
Study 26319228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) devices (MiniMed and Animas pumps)
Number of subjects: 43
Study 26319228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) and Subcutaneous (SC) infusion sets
Number of subjects: 43
Study 23381675 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-mechanical (SM) group
Number of subjects: 155
Study 23381675 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn (HS) group
Number of subjects: 155
Study 23381675 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled (CS) group
Number of subjects: 155
Study 20687305 — intervention group
Group type: COMPARATOR
Intervention: pacifier‐activated‐lullaby system (PAL) with one 15‐minute trial
Number of subjects: 68
Study 20687305 — intervention group
Group type: COMPARATOR
Intervention: pacifier‐activated‐lullaby system (PAL) with three 15‐minute trials
Number of subjects: 68
Study 20687305 — intervention group
Group type: COMPARATOR
Intervention: pacifier‐activated‐lullaby system (PAL)
Number of subjects: 68
Study 19090877 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/verapamil SR (T/V) fixed-dose combination (FDC)
Number of subjects: 304
Study 19090877 — intervention group
Group type: COMPARATOR
Intervention: Benazepril/amlodipine (B/A) fixed-dose combination (FDC)
Number of subjects: 304
Study 16868321 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 1 mL of 2% prilocaine using the peppering technique
Number of subjects: 44
Study 16868321 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of 2% prilocaine combined with 2 mL of autologous blood
Number of subjects: 44
Study 16868321 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of 2% prilocaine mixed with 40 mg of methylprednisolone acetate
Number of subjects: 44
Study 12956200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer
Number of subjects: 0
Study 12956200 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer
Number of subjects: 0
Study 12956200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nail lacquer with oral antifungal agent
Number of subjects: 0
Study 12956200 — intervention group
Group type: COMPARATOR
Intervention: Other topical agents
Number of subjects: 0
Study 11130156 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step attendance
Number of subjects: 99
Study 8862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR)
Number of subjects: 50
Study 8862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IRR)
Number of subjects: 50
Study 8862011 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (P‐gp negative)
Number of subjects: 50
Study 8862011 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (P‐gp positive)
Number of subjects: 50
Study 8862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IRR) in group 2
Number of subjects: 50
Study 8862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) in group 2
Number of subjects: 50
Study 1621484 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 8
Study 1621484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1621484 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 8
Study 6142748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol 4 mg
Number of subjects: 12
Study 6142748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pirbuterol 15 mg
Number of subjects: 12
Study 6142748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (500 microgram and 5 mg)
Number of subjects: 12
Study 31541454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized real-world evidence (RWE)
Number of subjects: 0
Study 31541454 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 28986072 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication abortion
Number of subjects: 643
Study 28986072 — intervention group
Group type: COMPARATOR
Intervention: Aspiration abortion
Number of subjects: 643
Study 26785362 — intervention group
Group type: EXPERIMENTAL
Intervention: Display ban condition
Number of subjects: 1313
Study 26785362 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packs and ads
Number of subjects: 1313
Study 25456022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumin powder (3 g/d with yogurt for 3 months)
Number of subjects: 88
Study 25456022 — intervention group
Group type: COMPARATOR
Intervention: Control (yogurt without cumin powder for 3 months)
Number of subjects: 88
Study 22217980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine emulsion infused in duodenum
Number of subjects: 15
Study 22217980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine emulsion infused in ileum
Number of subjects: 15
Study 22217980 — intervention group
Group type: COMPARATOR
Intervention: Coarse emulsion infused in duodenum
Number of subjects: 15
Study 22217980 — intervention group
Group type: COMPARATOR
Intervention: Coarse emulsion infused in ileum
Number of subjects: 15
Study 23051942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Sound Technology (MST)
Number of subjects: 42
Study 23051942 — intervention group
Group type: COMPARATOR
Intervention: Non-practitioners (Control)
Number of subjects: 42
Study 16319909 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 32
Study 16319909 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 14741074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathyl (study drug)
Number of subjects: 264
Study 14741074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 11048827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 127
Study 11048827 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study 9076210 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 17
Study 9076210 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 17
Study 9076210 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gelatin)
Number of subjects: 17
Study 8093113 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy in 30 fractions
Number of subjects: 941
Study 8093113 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 or 36 Gy in 10 or 12 fractions
Number of subjects: 941
Study 8093113 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in five fractions
Number of subjects: 941
Study 3081600 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study 3081600 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study 30941472 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional closure of a patent foramen ovale (PFO)
Number of subjects: 0
Study 30941472 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 30941472 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulation
Number of subjects: 0
Study 30941472 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO occluder implantation
Number of subjects: 0
Study 27460262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin-coated fortified rice with 400 μg 13C5-PteGlu
Number of subjects: 26
Study 27460262 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated fortified rice with 400 μg 13C5-PteGlu
Number of subjects: 26
Study 27460262 — intervention group
Group type: COMPARATOR
Intervention: Aqueous 400 μg 13C5-PteGlu
Number of subjects: 26
Study 26111104 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and Cyclophosphamide (EC)
Number of subjects: 198
Study 26111104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF)
Number of subjects: 198
Study 26111104 — intervention group
Group type: COMPARATOR
Intervention: nab-Paclitaxel and Capecitabine (nPX)
Number of subjects: 198
Study 23885722 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoosmolar enema (Normosol-R)
Number of subjects: 9
Study 23885722 — intervention group
Group type: COMPARATOR
Intervention: Hyperosmolar enema (Fleet)
Number of subjects: 9
Study 23885722 — intervention group
Group type: COMPARATOR
Intervention: Hypoosmolar enema (distilled water)
Number of subjects: 9
Study 23885722 — intervention group
Group type: EXPERIMENTAL
Intervention: All enema types
Number of subjects: 9
Study 21246188 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 1.5 mg
Number of subjects: 32
Study 21246188 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmirtazapine 4.5 mg
Number of subjects: 32
Study 21246188 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 32
Study 19513170 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group received training to assess and teach correct inhaler techniques and were provided with patient education tools.
Number of subjects: 31
Study 19513170 — intervention group
Group type: COMPARATOR
Intervention: Control group delivered standard care without additional training.
Number of subjects: 31
Study 17886555 — intervention group
Group type: COMPARATOR
Intervention: High-frequency rTMS at 5 Hz
Number of subjects: 0
Study 17886555 — intervention group
Group type: COMPARATOR
Intervention: High-frequency rTMS at 10 Hz
Number of subjects: 0
Study 17886555 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS at 1 Hz
Number of subjects: 0
Study 17886555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (5 or 10 Hz) in noncerebral lesions
Number of subjects: 0
Study 16317969 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom trays with 10% carbamide peroxide gel worn overnight for 2 weeks
Number of subjects: 57
Study 16317969 — intervention group
Group type: COMPARATOR
Intervention: 10% hydrogen peroxide polyethylene strips worn for 30 minutes twice a day for 2 weeks
Number of subjects: 57
Study 16212329 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular titanium cages
Number of subjects: 36
Study 16212329 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 36
Study 9596324 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine premedication (0.6 mg)
Number of subjects: 100
Study 9596324 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (1 mL)
Number of subjects: 100
Study 7674696 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapies for acute ischemic syndromes
Number of subjects: 0
Study 7674696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective organization of systems
Number of subjects: 0
Study 1982831 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO subcutaneous route (s.c) at doses of 20 u/kg daily
Number of subjects: 19
Study 1982831 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO subcutaneous route (s.c) at doses of 2000 units twice a week
Number of subjects: 19
Study 1982831 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO intraperitoneal route (i.p) at doses of 4000 u/day, three days a week
Number of subjects: 19
Study 1982831 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EPO doses and outcomes between groups
Number of subjects: 19
Study 369361 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg atropine sulfate
Number of subjects: 6
Study 369361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg glucagon
Number of subjects: 6
Study 369361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31053157 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended internal-external facilitation
Number of subjects: 9
Study 31053157 — intervention group
Group type: COMPARATOR
Intervention: Control (non-intervened sites)
Number of subjects: 9
Study 27942980 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced maximal exercise protocol (SPV)
Number of subjects: 44
Study 27942980 — intervention group
Group type: COMPARATOR
Intervention: Traditional ramp protocol (RAMP)
Number of subjects: 44
Study 26111923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored post-session D-cycloserine (DCS) administration
Number of subjects: 156
Study 26111923 — intervention group
Group type: COMPARATOR
Intervention: Untailored post-session D-cycloserine (DCS)
Number of subjects: 156
Study 26111923 — intervention group
Group type: COMPARATOR
Intervention: Untailored pre-session D-cycloserine (DCS)
Number of subjects: 156
Study 26111923 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 156
Study 26111923 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) prior to fear extinction retention experiment
Number of subjects: 156
Study 26111923 — intervention group
Group type: COMPARATOR
Intervention: Placebo prior to fear extinction retention experiment
Number of subjects: 156
Study 24019551 — intervention group
Group type: EXPERIMENTAL
Intervention: GM2-KLH/QS-21 vaccination
Number of subjects: 1314
Study 24019551 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1314
Study 21613440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cam-type deformities
Number of subjects: 2081
Study 21613440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pincer-type deformities
Number of subjects: 2081
Study 21613440 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover sign
Number of subjects: 2081
Study 19906504 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 473
Study 19906504 — intervention group
Group type: COMPARATOR
Intervention: acarbose
Number of subjects: 473
Study 16947097 — intervention group
Group type: EXPERIMENTAL
Intervention: Written advice from the paediatrician
Number of subjects: 40
Study 16947097 — intervention group
Group type: COMPARATOR
Intervention: No additional information about cotinine levels
Number of subjects: 40
Study 15230794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg intramuscular)
Number of subjects: 72
Study 15230794 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine (20 mg intramuscular)
Number of subjects: 72
Study 11878523 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.2% bupivacaine 8 ml h(‐1) (bupi group)
Number of subjects: 40
Study 11878523 — intervention group
Group type: COMPARATOR
Intervention: Epidural 0.2% bupivacaine/morphine 50 microg at 4 ml h(‐1) (bupi/morph group)
Number of subjects: 40
Study 9621380 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 212
Study 9621380 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal chorionic villus sampling
Number of subjects: 212
Study 8169617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine administration
Number of subjects: 852
Study 2656527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 50
Study 2656527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50